We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that ... Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. Show more
Ask ADVFN Intelligence (AI)
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second...
CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA® (vonoprazan) tablets to its national formularies for its more than 26 million commercially insured...
Management to host conference call on Thursday, August 8, 2024, at 8:30 am ET FLORHAM PARK, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.86 | -4.60385438972 | 18.68 | 19 | 17.12 | 797195 | 17.84966307 | CS |
| 4 | 1.52 | 9.32515337423 | 16.3 | 19.675 | 15.73 | 1106339 | 18.1831911 | CS |
| 12 | 7.6 | 74.3639921722 | 10.22 | 19.675 | 10.09 | 928048 | 14.58996624 | CS |
| 26 | 7.49 | 72.5072604066 | 10.33 | 19.675 | 8.74 | 756468 | 12.79380532 | CS |
| 52 | 7.54 | 73.3463035019 | 10.28 | 19.675 | 6.065 | 706922 | 10.88947043 | CS |
| 156 | -14.41 | -44.7098976109 | 32.23 | 34.36 | 5.84 | 417153 | 11.33406107 | CS |
| 260 | -6.495 | -26.7119062307 | 24.315 | 64.54 | 5.84 | 289787 | 14.46162975 | CS |
Monksdream
2 weeks ago
MiamiGent
2 months ago
MiamiGent
2 months ago
MiamiGent
2 months ago
FALCON1
2 months ago
MiamiGent
2 months ago
MiamiGent
2 months ago
MiamiGent
2 months ago
MiamiGent
2 months ago
MiamiGent
2 months ago
Monksdream
5 months ago
Monksdream
7 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
